12 weeks on retatrutide Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide Dosing Schedule: a 12-week

The effectiveness and safety of existing ferroptosis-targeting medicines must be confirmed via clinical studies

Norvell, T., Kumar, P., & Contractor, S

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug, and forecasts show that by 2030, 1 in 10 Americans will likely be using these medications

[2] The lips have a greater tendency to dry out in cold, dry weather

Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: implications for Autoimmune Diseases